<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2020-3-45-49</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-1045</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>Клинические особенности анкилозирующего спондилита у пациентов с вторичным АА-амилоидозом</article-title><trans-title-group xml:lang="en"><trans-title>Clinical features of ankylosing spondylitis in patients with secondary AA amyloidosis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Румянцева</surname><given-names>Д. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Rumyantseva</surname><given-names>D. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дарья Гаврильевна Румянцева</p><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>Daria Gavrilyevna Rumyantseva</p><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><email xlink:type="simple">rumiantceva01@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Агафонова</surname><given-names>Е. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Agafonova</surname><given-names>E. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Красненко</surname><given-names>С. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Krasnenko</surname><given-names>S. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Старкова</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Starkova</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Урумова</surname><given-names>М. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Urumova</surname><given-names>M. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Эрдес</surname><given-names>Ш.</given-names></name><name name-style="western" xml:lang="en"><surname>Erdes</surname><given-names>Sh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>21</day><month>09</month><year>2020</year></pub-date><volume>14</volume><issue>3</issue><fpage>45</fpage><lpage>49</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Румянцева Д.Г., Агафонова Е.М., Красненко С.О., Старкова А.С., Урумова М.М., Эрдес Ш., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Румянцева Д.Г., Агафонова Е.М., Красненко С.О., Старкова А.С., Урумова М.М., Эрдес Ш.</copyright-holder><copyright-holder xml:lang="en">Rumyantseva D.G., Agafonova E.M., Krasnenko S.O., Starkova A.S., Urumova M.M., Erdes S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/1045">https://mrj.ima-press.net/mrj/article/view/1045</self-uri><abstract><p>Почечный АА-амилоидоз – самый тяжелый тип патологии почек у пациентов с анкилозирующим спондилитом (АС). Нередко характерные симптомы АА-амилоидоза при ревматических заболеваниях не проявляются годами, затрудняя его раннюю диагностику и начало адекватной терапии.</p><p>Цель исследования – выявление особенностей клинической картины АС, осложненного вторичным АА-амилоидозом.</p><sec><title>Пациенты и методы</title><p>Пациенты и методы. В исследование включено 9 больных АС (согласно модифицированным Нью-Йоркским критериям, 1984) с гистологически подтвержденным вторичным АА-амилоидозом (1-я группа). Во 2-ю группу (группа сравнения) вошли 216 пациентов с АС без амилоидоза.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. У пациентов 1-й группы возраст дебюта АС был значительно меньше, а длительность болезни – в 4 раза больше, чем у больных 2-й группы. Все больные с АА-амилоидозом имели энтезит и артрит, в том числе тазобедренных суставов. Индексы BASDAI и ASDAS-СРБ, а также острофазовый показатель воспаления – СРБ – у пациентов с АА-амилоидозом были выше, чем в группе сравнения.</p></sec><sec><title>Заключение</title><p>Заключение. Особенностью клинической картины АС, осложненного вторичным АА-амилоидозом, являются большая длительность заболевания и высокая частота ювенильного начала, внеаксиальных проявлений (артрит, коксит и энтезит), а также высокая активность системного воспаления.</p></sec></abstract><trans-abstract xml:lang="en"><p>Renal AA amyloidosis is the most severe type of renal pathology in patients with ankylosing spondylitis (AS). The characteristic symptoms of AA amyloidosis in rheumatic diseases do not often occur for years, making it difficult to diagnose it early and to start adequate therapy.</p><sec><title>Objective</title><p>Objective: to identify the clinical features of AS complicated by secondary AA amyloidosis.</p></sec><sec><title>Patients and methods</title><p>Patients and methods. The investigation enrolled 9 patients with AS (according to the 1984 modified New York criteria) and histologically confirmed secondary AA amyloidosis (Group 1). A comparison group included 216 AS patients without amyloidosis (Group 2).</p></sec><sec><title>Results and discussion</title><p>Results and discussion. In Group 1 patients, the age at the onset of AS was significantly less and the disease duration was 4 times longer than those in Group 2. All the patients with AA amyloidosis had enthesitis and arthritis, including those of the hip joints. The scores of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP), and the acute phase inflammation index CRP were higher in Group 1 than in Group 2.</p></sec><sec><title>Conclusion</title><p>Conclusion. The clinical feature of AS complicated by secondary AA-amyloidosis is the long duration of the disease and the high frequency of juvenile onset, non-axial manifestations (arthritis, coxitis and enteritis), as well as the high activity of systemic inflammation.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>анкилозирующий спондилит</kwd><kwd>спондилоартриты</kwd><kwd>АА-амилоидоз</kwd><kwd>амилоид</kwd></kwd-group><kwd-group xml:lang="en"><kwd>ankylosing spondylitis</kwd><kwd>spondyloarthritides</kwd><kwd>AA amyloidosis</kwd><kwd>amyloid</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнено в рамках поисковой темы «Разработка методов терапии рефрактерного, тяжелого анкилозирующего спондилита» (НИОКР АААА-А20-120041390035-8).</funding-statement><funding-statement xml:lang="en">The investigation has been conducted within the framework of the exploratory topic «Development of treatments for refractory, severe ankylosing spondylitis» (R&amp;D AAAA-A20-120041390035-8).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Эрдес ШФ, Бадокин ВВ, Бочкова АГ и др. О терминологии спондилоартритов. Научно-практическая ревматология. 2015;53(6):657-60. doi: 10.14412/19954484-2015-657-660</mixed-citation><mixed-citation xml:lang="en">Erdes ShF, Badokin VV, Bochkova AG, et al. On the terminology of spondyloarthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2015;53(6): 657-60. (In Russ.). doi: 10.14412/19954484-2015-657-660</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Strobel ES, Fritschka E. Renal diseases in ankylosing spondylitis: Review of the literature illustrated by case reports. Clin Rheumatol. 1998;17(6):524-30. doi: 10.1007/BF01451293.</mixed-citation><mixed-citation xml:lang="en">Strobel ES, Fritschka E. Renal diseases in ankylosing spondylitis: Review of the literature illustrated by case reports. Clin Rheumatol. 1998;17(6):524-30. doi: 10.1007/BF01451293.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Шавловский ММ. Молекулярные и генетические основы этиопатогенеза амилоидозов. Медицинский академический журнал 2010;10(4):63-81.</mixed-citation><mixed-citation xml:lang="en">Shavlovskii MM. Molecular and genetic basis of the pathogenesis of the amyloidoses. Meditsinskii akademicheskii zhurnal 2010; 10(4):63-81. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid. 2016 Dec;23(4):209-13. doi: 10.1080/13506129.2016.1257986. Epub 2016 Nov 24.</mixed-citation><mixed-citation xml:lang="en">Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid. 2016 Dec;23(4):209-13. doi: 10.1080/13506129.2016.1257986. Epub 2016 Nov 24.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Molto A, Etcheto A, van der Heijde D, et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis. 2016 Jun;75(6):1016-23. doi: 10.1136/annrheumdis-2015-208174. Epub 2015 Oct 21.</mixed-citation><mixed-citation xml:lang="en">Molto A, Etcheto A, van der Heijde D, et al. Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study. Ann Rheum Dis. 2016 Jun;75(6):1016-23. doi: 10.1136/annrheumdis-2015-208174. Epub 2015 Oct 21.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Yamada T. Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med. 1999 Apr;37(4):381-8. doi: 10.1515/CCLM.1999.063.</mixed-citation><mixed-citation xml:lang="en">Yamada T. Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clin Chem Lab Med. 1999 Apr;37(4):381-8. doi: 10.1515/CCLM.1999.063.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Hagihara K, Nishikawa T, Isobe T, et al. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun. 2004 Feb 6; 314(2):363-9. doi: 10.1016/j.bbrc.2003.12.096.</mixed-citation><mixed-citation xml:lang="en">Hagihara K, Nishikawa T, Isobe T, et al. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun. 2004 Feb 6; 314(2):363-9. doi: 10.1016/j.bbrc.2003.12.096.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Okuda Y. AA amyloidosis – Benefits and prospects of IL-6 inhibitors. Mod Rheumatol. 2019 Mar;29(2):268-74. doi: 10.1080/14397595.2018.1515145. Epub 2018 Oct 2.</mixed-citation><mixed-citation xml:lang="en">Okuda Y. AA amyloidosis – Benefits and prospects of IL-6 inhibitors. Mod Rheumatol. 2019 Mar;29(2):268-74. doi: 10.1080/14397595.2018.1515145. Epub 2018 Oct 2.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Fernandez-Nebro A, Olive A, Castro MC, et al. Long-term TNF-alpha blockade in patients with amyloid A amyloidosis complicating rheumatic diseases. Am J Med. 2010 May;123(5):454-61. doi: 10.1016/j.amjmed.2009.11.010.</mixed-citation><mixed-citation xml:lang="en">Fernandez-Nebro A, Olive A, Castro MC, et al. Long-term TNF-alpha blockade in patients with amyloid A amyloidosis complicating rheumatic diseases. Am J Med. 2010 May;123(5):454-61. doi: 10.1016/j.amjmed.2009.11.010.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 2006 Sep;54(9): 2997-3000. doi: 10.1002/art.22118.</mixed-citation><mixed-citation xml:lang="en">Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum. 2006 Sep;54(9): 2997-3000. doi: 10.1002/art.22118.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Sato H, Sakai T, Sugaya T, et al. Tocilizumab dramatically ameliorated lifethreatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis. Clin Rheumatol. 2009 Sep;28(9):1113-6. doi: 10.1007/s10067-009-1185-0. Epub 2009 May 13..</mixed-citation><mixed-citation xml:lang="en">Sato H, Sakai T, Sugaya T, et al. Tocilizumab dramatically ameliorated lifethreatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis. Clin Rheumatol. 2009 Sep;28(9):1113-6. doi: 10.1007/s10067-009-1185-0. Epub 2009 May 13..</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Magro-Checa C, Navas-Parejo Casado A, Borrego-Garcia E, et al. Successful use of tocilizumab in a patient with nephrotic syndrome due to a rapidly progressing AA amyloidosis secondary to latent tuberculosis. Amyloid. 2011 Dec;18(4):235-9. doi: 10.3109/13506129.2011.613962. Epub 2011 Oct 12.</mixed-citation><mixed-citation xml:lang="en">Magro-Checa C, Navas-Parejo Casado A, Borrego-Garcia E, et al. Successful use of tocilizumab in a patient with nephrotic syndrome due to a rapidly progressing AA amyloidosis secondary to latent tuberculosis. Amyloid. 2011 Dec;18(4):235-9. doi: 10.3109/13506129.2011.613962. Epub 2011 Oct 12.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Inoue D, Arima H, Kawanami C, et al. Excellent therapeutic effect of tocilizumab on intestinal amyloid A deposition secondary to active rheumatoid arthritis. Clin Rheumatol. 2010 Oct;29(10):1195-7. doi: 10.1007/s10067-010-1422-6. Epub 2010 Mar 15.</mixed-citation><mixed-citation xml:lang="en">Inoue D, Arima H, Kawanami C, et al. Excellent therapeutic effect of tocilizumab on intestinal amyloid A deposition secondary to active rheumatoid arthritis. Clin Rheumatol. 2010 Oct;29(10):1195-7. doi: 10.1007/s10067-010-1422-6. Epub 2010 Mar 15.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Nishida S, Hagihara K, Shima Y, et al. Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. Ann Rheum Dis. 2009 Jul; 68(7):1235-6. doi: 10.1136/ard.2008.099267.</mixed-citation><mixed-citation xml:lang="en">Nishida S, Hagihara K, Shima Y, et al. Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. Ann Rheum Dis. 2009 Jul; 68(7):1235-6. doi: 10.1136/ard.2008.099267.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Kishida D, Okuda Y, Onishi M, et al. Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis. Mod Rheumatol. 2011 Apr;21(2): 215-8. doi: 10.1007/s10165-010-0365-8. Epub 2010 Oct 8.</mixed-citation><mixed-citation xml:lang="en">Kishida D, Okuda Y, Onishi M, et al. Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis. Mod Rheumatol. 2011 Apr;21(2): 215-8. doi: 10.1007/s10165-010-0365-8. Epub 2010 Oct 8.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Okuda Y, Ohnishi M, Matoba K, et al. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol. 2014 Jan;24(1):137-43. doi: 10.3109/14397595.2013.854048.</mixed-citation><mixed-citation xml:lang="en">Okuda Y, Ohnishi M, Matoba K, et al. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol. 2014 Jan;24(1):137-43. doi: 10.3109/14397595.2013.854048.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Hunter J, McGregor L. Do inflammatory rheumatic diseases still cause as much harm through amyloidosis? Amyloid. 2011 Jun;18 Suppl 1:208-10. doi: 10.3109/13506129.2011.574354078.</mixed-citation><mixed-citation xml:lang="en">Hunter J, McGregor L. Do inflammatory rheumatic diseases still cause as much harm through amyloidosis? Amyloid. 2011 Jun;18 Suppl 1:208-10. doi: 10.3109/13506129.2011.574354078.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Подряднова МВ, Балабанова РМ, Урумова ММ, Эрдес ШФ. Взаимосвязь клинических характеристик анкилозирующего спондилита с трудоспособностью и производительностью труда. Научно-практическая ревматология. 2014;52(5):513-9. doi: 10.14412/19954484-2014-513-519</mixed-citation><mixed-citation xml:lang="en">Podryadnova MV, Balabanova RM, Urumova MM, Erdes ShF. Correlation between clinical characteristics of ankylosing spondylitis and work capacity and productivity. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2014; 52(5):513-9. (In Russ.). doi: 10.14412/19954484-2014-513-519</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Дубинина ТВ, Гайдукова ИЗ, Годзенко АА и др. Рекомендации по оценке активности болезни и функционального состояния больных анкилозирующим спондилитом в клинической практике. Научно-практическая ревматология. 2017;55(4):344-50. doi: 10.14412/1995-4484-2017-344-350</mixed-citation><mixed-citation xml:lang="en">Dubinina TV, Gaidukova IZ, Godzenko AA, et al. Guidelines for the assessment of disease activity and functional status in patients with ankylosing spondylitis in clinical practice. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2017;55(4):344-50. (In Russ.). doi: 10.14412/1995-4484-2017-344-350</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Villiaumey J, Lejeune E, Avouac B, Horreard P. Spondylarthrite ankylosante et amylose. Ann Med Interne (Paris). 1978 Jan; 129(1):67-71.</mixed-citation><mixed-citation xml:lang="en">Villiaumey J, Lejeune E, Avouac B, Horreard P. Spondylarthrite ankylosante et amylose. Ann Med Interne (Paris). 1978 Jan; 129(1):67-71.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Cristoph R, Genth E, Hartl W. Incidence of amyloidosis in ankylosing spondylitis. Scand J Rheumatol. 1975;8:39.</mixed-citation><mixed-citation xml:lang="en">Cristoph R, Genth E, Hartl W. Incidence of amyloidosis in ankylosing spondylitis. Scand J Rheumatol. 1975;8:39.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Okuda Y, Yamada T, Matsuura M, et al. Ageing: a risk factor for amyloid A amyloidosis in rheumatoid arthritis. Amyloid. 2011 Sep; 18(3):108-11. doi: 10.3109/13506129.2011.582198. Epub 2011 Jun 1.</mixed-citation><mixed-citation xml:lang="en">Okuda Y, Yamada T, Matsuura M, et al. Ageing: a risk factor for amyloid A amyloidosis in rheumatoid arthritis. Amyloid. 2011 Sep; 18(3):108-11. doi: 10.3109/13506129.2011.582198. Epub 2011 Jun 1.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Hsu HC, Zhou T, Yang PA, et al. Increased acute-phase response and renal amyloidosis in aged CD2-fastransgenic mice. J Immunol. 1997 Jun 15;158(12):5988-96.</mixed-citation><mixed-citation xml:lang="en">Hsu HC, Zhou T, Yang PA, et al. Increased acute-phase response and renal amyloidosis in aged CD2-fastransgenic mice. J Immunol. 1997 Jun 15;158(12):5988-96.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Barbouch S, Hajji M, Jaziri F, et al. Renal amyloidosis in ankylosing spondylitis: a monocentric study and review of literature. Saudi J Kidney Dis Transpl. Mar-Apr 2018; 29(2):386-91. doi: 10.4103/1319-2442.229291.</mixed-citation><mixed-citation xml:lang="en">Barbouch S, Hajji M, Jaziri F, et al. Renal amyloidosis in ankylosing spondylitis: a monocentric study and review of literature. Saudi J Kidney Dis Transpl. Mar-Apr 2018; 29(2):386-91. doi: 10.4103/1319-2442.229291.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Hajjaj-Hassouni N, Laghrissi S, Khalil A, et al. Ankylosing spondylitis and amyloidosis. Apropos of 2 cases. Rev Rhum Mal Osteoartic. 1982 Oct;49(10):687-91.</mixed-citation><mixed-citation xml:lang="en">Hajjaj-Hassouni N, Laghrissi S, Khalil A, et al. Ankylosing spondylitis and amyloidosis. Apropos of 2 cases. Rev Rhum Mal Osteoartic. 1982 Oct;49(10):687-91.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Lance NJ, Curran JJ. Amyloidosis in a case of ankylosing spondylitis with a review of the literature. J Rheumatol. 1991 Jan; 18(1):100-3.</mixed-citation><mixed-citation xml:lang="en">Lance NJ, Curran JJ. Amyloidosis in a case of ankylosing spondylitis with a review of the literature. J Rheumatol. 1991 Jan; 18(1):100-3.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Gomez-Casanovas E., Sanmarti R., Sole M, et al. The clinical significance of amyloid fat deposits in rheumatoid arthritis: a systematic long-term followup study using abdominal fat aspiration. Arthritis Rheum. 2001 Jan;44(1):66-72. doi: 10.1002/15290131(200101)44:1&lt;66::AID-ANR10&gt;3.0.CO;2-H.</mixed-citation><mixed-citation xml:lang="en">Gomez-Casanovas E., Sanmarti R., Sole M, et al. The clinical significance of amyloid fat deposits in rheumatoid arthritis: a systematic long-term followup study using abdominal fat aspiration. Arthritis Rheum. 2001 Jan;44(1):66-72. doi: 10.1002/15290131(200101)44:1&lt;66::AID-ANR10&gt;3.0.CO;2-H.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Муравьев ЮВ, Раденска-Лаповок СГ, Алексеева АВ и др. Необычное течение АА-амилоидоза у больной ревматоидным артритом. Научно-практическая ревматология. 2009;47(2):73-5. doi: 10.14412/1995-4484-2009-462</mixed-citation><mixed-citation xml:lang="en">Murav'ev YuV, Radenska-Lapovok SG, Alekseeva AV, et al. Unusual course of AA amiloidosis in a patient with rheumatoid arthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2009;47(2):73-5. (In Russ.). doi: 10.14412/1995-4484-2009-462</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
